DEENOVA
16.1.2023 06:01:50 CET | Business Wire | Press release
Deenova confirms its undisputed leadership on the French Hospital Pharmacy Automation market by announcing six new contract awards in France of 10 market leading D3 ACCED mechatronic solutions through the previous victory at competitive UNIHA tender. Three have been awarded by both the Centre Hospitalier de Béziers and the Centre Hospitalier de Troyes, one has been awarded by the Etablissement public départemental de santé de Gorze, by the Etablissement public de santé mentale de l’Aube at Brienne-Le- Château, by the Centre Hospitalier Alpes-Leman at Contamine-sur-Arve, and finally by the Hôpital de Sallanches.
Loïc Bessin, Managing Director of Deenova France, proudly stated: “This is the best way to start 2023, and confirms our undisputed leadership in France. More than 50 healthcare institutions have chosen our robots, because of their reliability, speed and ease of use. We expect this trend to continue and even accelerate as the demand for solution to secure medication is growing significantly.”
Christophe Jaffuel, Chief Commercial Officer of Deenova, said: “I am extremely proud of the results of our French organization, that has been scoring 3 years of record sales consecutively. France has been a major contributor to the European revenue growth of the company, together with successful market entries in Germany, Spain, UK and Poland.”
The Centre Hospitalier de Béziers is part of the Groupement Hospitalier de Territoire Ouest-Hérault, in the Occitanie region of southern France, providing emergency assistance, surgical and medical specialties, psychological support and screenings.
Gorze is a commune of the Grand Est Region in north-eastern France and the Etablissement public départemental de santé has 310 beds.
In the Grand Est Region there is also the Etablissement public de santé mentale de l’Aube at Brienne-Le- Château, an adult psychiatric clinic with day hospital, geronto psychiatry beds and a medium term unit receiving prisoners.
Centre Hospitalier de Troyes is in the capital of the Aube department and has 11 centers covering all medical, surgical and medico-technical disciplines, with more than 1,000 beds.
Contamine-sur-Arve is a commune in the Auvergne-Rhône-Alpes region of eastern France. The Centre Hospitalier Alpes-Leman has 700 beds and places with more than 2,000 professionals assisting 1,300 people every day.
The Hôpital de Sallanches is one of the 5 sites of the Hôpitaux du Pays du Mont Blanc, all located in the heart of 3 worldwide famous ski areas, at the foot of Mont-Blanc, in the Haute-Savoie department. More than 1,000 health professionals working in 6 committed poles, from Surgery & Acute Care to Geriatrics, provide health coverage to 120,000 permanent inhabitants and many seasonal tourists.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information on its market leading solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230115005028/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 12:00:00 CET | Press release
Lyten announces the establishment of its next Lyten Industrial Hub in Gdańsk, Poland. The hub will bring together key manufacturing and digital resources to support energy infrastructure, the development of artificial intelligence, and the defense sector. In February 2026, Lyten announced the creation of the first Lyten Industrial Hub in Sweden, combining battery production operations there with a 1 GW AI data center campus. Lyten plans to complete its feasibility study by the end of 2026 to determine the full development plan Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
